CONCLUSION
IRON DEFICIENCY ANEMIA, DYSMENORRHEA, PMS
In conclusion, CUR was significantly more effective versus placebo in decreasing serum hsCRP, an inflammatory biomarker, in young women with PMS and dysmenorrhea. There are no significant differences between CUR intake and placebo regarding to the iron profile, while no treatment‐induce iron deficiency anemia were registered. However, further studies are warranted to get a definitive conclusion.